Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and DDI Study of Bexobrutideg (NX-5948)
NCT06593457Phase 1Completed
- Sponsor
- Nurix Therapeutics
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bexobrutideg in B cell malignancies, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 2 more (3 arms), sponsored by Nurix Therapeutics. Primary endpoints: Area Under the Curve from time zero to last measurable concentration at 9 weeks, Area Under the Curve from time zero to infinity at 9 weeks and 1 more. Started Aug 2024; status: completed.
02
Drugs
bexobrutideg
03
Conditions
B cell malignancieschronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)non-Hodgkin lymphoma (NHL)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT06593457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06593457.